Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 10.8 2.56% 0.27
SYRS closed up 2.56 percent on Friday, January 19, 2018, on 40 percent of normal volume.
1 Watcher
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Jan 19 Weak + Overbought Other 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 18 Narrow Range Bar Range Contraction 2.56%
Jan 18 Wide Bands Range Expansion 2.56%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.18%
Jan 17 Upper Bollinger Band Walk Strength -0.18%
Jan 17 Weak + Overbought Other -0.18%
Jan 17 Wide Bands Range Expansion -0.18%
Jan 17 Overbought Stochastic Strength -0.18%

Older signals for SYRS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.38
52 Week Low 6.3
Average Volume 378,635
200-Day Moving Average 15.616
50-Day Moving Average 11.2621
20-Day Moving Average 10.1345
10-Day Moving Average 10.464
Average True Range 0.7289
ADX 15.05
+DI 18.51
-DI 17.34
Chandelier Exit (Long, 3 ATRs ) 8.9233
Chandelier Exit (Short, 3 ATRs ) 11.3367
Upper Bollinger Band 10.9992
Lower Bollinger Band 9.2698
Percent B (%b) 0.88
BandWidth 17.064483
MACD Line -0.1605
MACD Signal Line -0.3732
MACD Histogram 0.2127
Fundamentals Value
Market Cap 283.61 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -5.12
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.57
Resistance 3 (R3) 11.54 11.27 11.44
Resistance 2 (R2) 11.27 11.07 11.28 11.39
Resistance 1 (R1) 11.03 10.95 11.15 11.06 11.35
Pivot Point 10.76 10.76 10.82 10.77 10.76
Support 1 (S1) 10.52 10.56 10.64 10.55 10.25
Support 2 (S2) 10.25 10.44 10.26 10.21
Support 3 (S3) 10.01 10.25 10.16
Support 4 (S4) 10.04